SOBERANA 02

SOBERANA 02 (FINLAY-FR-2) is a COVID-19 conjugate vaccine developed by the Finlay Vaccine Institute (IFV) in collaboration with the Center for Molecular Immunology (CIM). The vaccine utilizes a recombinant SARS-CoV-2 Receptor Binding Domain (RBD) protein, produced in CHO cells, which is chemically conjugated to a tetanus toxoid carrier protein and adsorbed onto aluminum hydroxide gel. This conjugate technology, traditionally used in bacterial vaccines, is designed to enhance the immune response by recruiting T-cell help for B-cells, thereby improving the production of high-affinity neutralizing antibodies and immunological memory. It is typically administered as a two-dose primary series, often followed by a third heterologous dose of SOBERANA Plus. The vaccine has received emergency use authorization in Cuba, Iran, Venezuela, and several other countries for both adult and pediatric use.

Brand names

SOBERANA 02SOBERANA02SOBERANA-02PasteurcovacPasteur

Other names

FINLAY-FR-2FINLAY-FR2FINLAY-FR 2Soberana 2Soberana2Soberana-2